Dimethyltryptamine is under clinical development by Mind Medicine MindMed and currently in Phase I for Psychiatric Disorders. According to GlobalData, Phase I drugs for Psychiatric Disorders have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Dimethyltryptamine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dimethyltryptamine (DMT) is under development for the treatment of psychiatric disorders. It is administered through intravenous route. DMT is an active ingredient in Ayahuasca and acts by targeting 5-hydroxytryptamine receptor 2A (5HT2A). It is a psychedelic drug.
Mind Medicine MindMed overview
Mind Medicine MindMed (MindMed) is a neuro-pharmaceutical company. It develops, discovers and deploys psychedelic inspired medicines to promote wellness, improve health, and alleviate suffering. MindMed is headquartered in New York, the US.
For a complete picture of Dimethyltryptamine’s drug-specific PTSR and LoA scores, buy the report here.